TNFRSF17 and Miyoshi myopathy: Another clinical trial utilized Crenigacestat (LY3039478; JSMD194) as a gamma-secretase inhibitor for MM patients with ide-cel in Phase I/II (KarMMa-7) (NCT04855136) and with anti-BCMA CAR T-cells (NCT03502577) [110].